Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency staff efforts dedicated to 351(k) reviews increased more than 10-fold in fiscal year 2015, Eastern Research Group says.
You may also be interested in...
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.